An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.

Related Keywords

Massachusetts , United States , Dana Farber Cancer Institute , Danielle Ellis , Patrick Wen , Keith Ligon , Rifaquat Rahman , Eudocia Quant Lee , Brian Alexander , Isabel Arrillaga , Division Of Neuropathology At Brigham , Study Co , Study Co First Author , Radiation Oncologist , Dana Farber Cancer , Individualized Screening Trial , Innovative Glioblastoma Therapy , Lorenzo Trippa , Bayesian Adaptive Randomization , Isabel Arrillaga Romany , Massachusetts General Hospital , Clinical Trial , Glioblastoma , Rain , Brain Tumor , Dancer , Chemotherapy , Children , Drugs , Hospital , Neratinib , Neuro Oncology , Ncology , Research , Herapeutics , Humor ,